$3.88
0.52% yesterday
Nasdaq, Sep 18, 10:00 pm CET
ISIN
US28106W1036
Symbol
EDIT
Sector
Industry

Editas Medicine, Inc. Stock price

$3.88
-0.22 5.37% 1M
-3.84 49.74% 6M
-6.25 61.70% YTD
-4.13 51.56% 1Y
-54.32 93.33% 3Y
-21.41 84.66% 5Y
-14.32 78.68% 10Y
Nasdaq, Closing price Wed, Sep 18 2024
+0.02 0.52%
ISIN
US28106W1036
Symbol
EDIT
Sector
Industry

Key metrics

Market capitalization $318.36m
Enterprise Value $77.95m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 1.16
P/S ratio (TTM) P/S ratio 4.75
P/B ratio (TTM) P/B ratio 1.37
Revenue growth (TTM) Revenue growth 247.03%
Revenue (TTM) Revenue $67.03m
EBIT (operating result TTM) EBIT $-213.02m
Free Cash Flow (TTM) Free Cash Flow $-171.54m
Cash position $279.11m
EPS (TTM) EPS $-2.36
P/E forward negative
P/S forward 11.73
EV/Sales forward 2.87
Short interest 27.66%
Show more

Is Editas Medicine, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,908 stocks worldwide.

Editas Medicine, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

19 Analysts have issued a Editas Medicine, Inc. forecast:

10x Buy
53%
9x Hold
47%

Analyst Opinions

19 Analysts have issued a Editas Medicine, Inc. forecast:

Buy
53%
Hold
47%

Financial data from Editas Medicine, Inc.

Assets
Dec '23
341 341
Cash 323 323
Claims 10 10
Inventories - -
Other current assets Other current assets Current assets 7.53 7.53
158 158
Property, plant and equipment 46 46
Financial assets 108 108
Intangible Assets - -
Other fixed assets Other assets Fixed assets 4.71 4.71
Total Assets 499 499
Liabilities
Dec '23
Equity 349 349
150 150
Current liabilities 63 63
Non-current liabilities 87 87
Total Capital 499 499

In millions USD.

Don't miss a Thing! We will send you all news about Editas Medicine, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Editas Medicine, Inc. Stock News

Neutral
Seeking Alpha
one day ago
Editas Medicine, Inc. (NASDAQ:EDIT ) 2024 Cantor Global Healthcare Conference September 17, 2024 1:20 PM ET Company Participants Gilmore O'Neill - CEO Conference Call Participants Eric Schmidt - Cantor Fitzgerald Eric Schmidt Good afternoon, everyone. My name is Eric Schmidt, and I'm one of the, biotechnology analyst at Cantor Fitzgerald.
Positive
24/7 Wall Street
12 days ago
There has been a noticeable shift in the stock market over the last two months.
Neutral
Seeking Alpha
13 days ago
Editas Medicine, Inc. (NASDAQ:EDIT ) Wells Fargo 2024 Healthcare Conference September 5, 2024 4:30 PM ET Company Participants Gilmore O'Neill - CEO Erick Lucera - CFO Conference Call Participants Yanan Zhu - Wells Fargo Securities Yanan Zhu Let's get started. Thanks, everyone, for being here.
More Editas Medicine, Inc. News

Company Profile

Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR), and CRISPR associated protein 9 (Cas9). The company was founded by Feng Zhang, Jennifer A. Doudna, George McDonald Church, J. Keith Joung and David R. Liu in September 2013 and is headquartered in Cambridge, MA.

Head office United States
CEO Gilmore O’Neill
Employees 265
Founded 2013
Website www.editasmedicine.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today